EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Treatment Outcomes With Novel Targeted and Immunotherapeutic Regimens in CAYA Hodgkin Lymphoma: A Retrospective Study

Mengqing Xie iD, Meng Yuan, Mengwei Ren, Jing Tian iD, Shengyu Zhou, Xiaohui He, Yan Qin, Peng Liu, Jianliang Yang, Mengyuan Han, Fei Ma iD, Sheng Yang und 1 weitere

Cancer Innovation · 2026-04 · 5 (2)

DOI: 10.1002/cai2.70050 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer Innovation, online erschienen am 16.03.2026. Verfasst von Mengqing Xie und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Oncology National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Scienc…. Die Arbeit nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Basic Research Program of China, National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

To evaluate the efficacy and safety of novel chemotherapy regimens, including brentuximab vedotin (BV) and immune checkpoint inhibitors (ICIs), in children, adolescents, and young adults (CAYA) with Hodgkin lymphoma (HL).

Methods

A retrospective analysis was conducted on untreated Stage IIB (bulky), III, or IV HL patients (≤ 24 years) who were admitted to Cancer Hospital of the Chinese Academy of Medical Sciences and Beijing Children's Hospital, Capital Medical University, from 2017 to 2024. The cohort compared conventional regimens with BV‑based therapies (BV‑AVD ± R). Furthermore, the efficacy and safety of ICIs were evaluated in relapsed/refractory cHL patients receiving second‑line or later therapy.

Results

In this comparison between BV and conventional regimens, 182 patients were enrolled. The median follow‐up was 38 months. No significant differences were observed in objective response rate (ORR) (96.4% vs 95.4%, p = 0.927) or progression‐free survival (PFS) rate (92.8% vs 95.3%, p = 0.466).However, the incidence of Grade 4 hematologic toxicity was significantly higher with conventional therapy compared to BV‐AVD±R (61.2% vs 25.6%, p < 0.001). The BV‐AVD group alone achieved a significantly higher ORR than the BV ‐AVD+R group (100% vs. 93.9%, p = 0.047), while there was no significant difference in PFS rate. However, the BV‐AVD + R group exhibited a significantly higher incidence of Grade 3–4 hematologic toxicities (78.8% vs. 20.0%, p = 0.023). Immune checkpoint inhibitors was well‐tolerated with infrequent adverse events, and 18/19 cases (94.7%) demonstrated treatment efficacy.

Conclusion

For patients with stage II Hodgkin lymphoma presenting with bulky disease, as well as those with stage III–IV disease, the BV‐AVD regimen is recommended as first‐line therapy, given its more favorable toxicity profile.Although ICIs represent a promising therapeutic approach, existing studies are constrained by limited sample sizes. Future research should focus on expanding patient cohorts to refine treatment strategies and ultimately improve clinical outcomes.

Schlagwörter

Stichwörter der Autor:innen

Hodgkin lymphomaadolescent and young adultbrentuximab vedotinimmune checkpoint inhibitors

Autor:innen und Institutionen

  • Department of Medical Oncology National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College Beijing China.
  • Hematology Center, Beijing Children's Hospital Capital Medical University Beijing China.
  • Department of Pediatric, Beijing Jishuitan Hospital Capital Medical University Beijing China.
  • Department of Pediatric, Beijing Shijitan Hospital Capital Medical University Beijing China.

ORCID-Profile: Mengqing Xie, Jing Tian, Fei Ma, Sidan Li

Förderung

  • National Basic Research Program of China
  • National Natural Science Foundation of China

Zitieren

APA

Xie, M., Yuan, M., Ren, M., Tian, J., Zhou, S., He, X., Qin, Y., Liu, P., Yang, J., Han, M., Ma, F., Yang, S., & Li, S. (2026). Treatment Outcomes With Novel Targeted and Immunotherapeutic Regimens in CAYA Hodgkin Lymphoma: A Retrospective Study. Cancer Innovation, 5(2). https://doi.org/10.1002/cai2.70050

Vancouver

Xie M, Yuan M, Ren M, Tian J, Zhou S, He X, et al. Treatment Outcomes With Novel Targeted and Immunotherapeutic Regimens in CAYA Hodgkin Lymphoma: A Retrospective Study. Cancer Innovation. 2026;5(2). doi:10.1002/cai2.70050

BibTeX
@article{Xie2026,
  author = {Xie, Mengqing and Yuan, Meng and Ren, Mengwei and Tian, Jing and Zhou, Shengyu and He, Xiaohui and Qin, Yan and Liu, Peng and Yang, Jianliang and Han, Mengyuan and Ma, Fei and Yang, Sheng and Li, Sidan},
  title = {Treatment Outcomes With Novel Targeted and Immunotherapeutic Regimens in CAYA Hodgkin Lymphoma: A Retrospective Study},
  journal = {Cancer Innovation},
  year = {2026},
  volume = {5},
  number = {2},
  doi = {10.1002/cai2.70050}
}
Kostenlos starten →